Axitinib

A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.

Also Known As:

AG 013736; AG-013736; AG013736; Inlyta; Benzamide, N- methyl- 2- ((3- ((E)- 2- (2- pyridinyl)ethenyl)- 1H- indazol- 6- yl)thio)-

Organic Chemicals: 140
- Amides: 2487
  - Benzamides: 115
    - Axitinib: 830
- Hydrocarbons: 1726
  - Cyclic Hydrocarbons: 96
    - Aromatic Hydrocarbons: 295
      - Benzene Derivatives: 17
        Benzoates: 430
        Benzamides: 115
        Axitinib: 830
- Carboxylic Acids: 986
  - Carbocyclic Acids
    - Benzoates: 430
      - Benzamides: 115
        Axitinib: 830
Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Azoles: 2199
    - Pyrazoles: 61
      - Indazoles: 183
        Axitinib: 830
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indazoles: 183
      - Axitinib: 830

Andree Boucher Selected Research

Andree Boucher Research Topics

Disease

Drug/Important Bio-Agent (IBA)